Researchers from Deutsches Krebsforschungszentrum DKFZ and affiliated organizations presented data for the novel inhibitor of DNA methyltransferase (DNMT) and histone methyltransferase G9a (HMT-G9a), CM-272, being developed for the treatment of acute myeloid leukemia (AML).
Shouyao Holdings (Beijing) Co. Ltd. has patented inhibitors of fibroblast growth factor receptor (FGFR), particularly FGFR2 and/or FGFR3, described as potentially useful for the treatment of cancer.
Shanghai Leadingtac Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a son of sevenless homolog 1 (SOS1) targeting moiety reported to be useful for the treatment of cancer, neurofibromatosis type 1, Costello syndrome, cardiofaciocutaneous syndrome and Noonan syndrome.
Even though HER3 is validated as a promising therapeutic target for cancer therapy, no HER3-targeting antibodies or antibody-drug conjugates (ADCs) have been approved for clinical use. Investigators at Duality Biologics (Suzhou) Co. Ltd. have developed DB-1310, a new HER3-targeting ADC being studied for the treatment of solid tumors, and published findings from preclinical characterization.
HERV-H LTR-associating protein 2 (HHLA2) is known to play immunosuppressive roles by interacting with killer cell immunoglobulin-like receptor 3DL3 (KIR3DL3). The expression of HHLA2 in cancer is associated with poor patient outcomes, making it a promising therapeutic target for immunotherapy. Nextpoint Therapeutics Inc. has presented data on their monoclonal antibodies NPX-267 and NPX-887, which target KIR3DL3 and HHLA2, respectively.
Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have synthesized GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
RSS
